Evidence map›Paper›PMID 41761389›Full record

ArticleThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease2026

Rifamycin-, macrolide-, and ethambutol-free combinations to treat

G D Boorgula, A Shrivastava, S Singh, R-A Galvez, P J McShane, M Devine, T Gumbo, S Srivastava

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

G D BoorgulaDivison of Infectious Diseases, Department of Medicine, School of Medicine, University of Texas at Tyler, Tyler, TX, USA.
A ShrivastavaDivison of Infectious Diseases, Department of Medicine, School of Medicine, University of Texas at Tyler, Tyler, TX, USA.
S SinghDivison of Infectious Diseases, Department of Medicine, School of Medicine, University of Texas at Tyler, Tyler, TX, USA.
R-A GalvezSection of Pulmonary and Critical Care, Department of Medicine, School of Medicine, University of Texas at Tyler, Tyler, TX, USA.
P J McShaneSection of Pulmonary and Critical Care, Department of Medicine, School of Medicine, University of Texas at Tyler, Tyler, TX, USA.
M DevineSection of Pulmonary and Critical Care, Department of Medicine, School of Medicine, University of Texas at Tyler, Tyler, TX, USA.
T GumboIMPI Biotech Consortium Inc., Tateguru, Zimbabwe.
S SrivastavaDivison of Infectious Diseases, Department of Medicine, School of Medicine, University of Texas at Tyler, Tyler, TX, USA;, Department of Cellular and Molecular Biology, University of Texas Health Science Centre at Tyler, Tyler, TX, USA.

Funding

Short course combination regimens for treatment of Mycobacterium avium pulmonary disease: a translational bench-to-bedside approachR01AI179827 · NIAID · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · PI Shashi Kant · 2024 to 2026
$1.7M
Reinforcing old warriors to treat Mycobacterium kansasii in shorter durationR21AI148096 · NIAID · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · PI KANT, SHASHI · 2020 to 2021
$413k
NIAID NIH HHS R01 AI179827NIAID NIH HHS R21 AI148096
6 · The paper itself

Abstract

<sec><title>OBJECTIVE</title>Poor sustained sputum culture conversion with guidelines-based therapy for

Indexed as

Anti-Bacterial AgentsAntitubercular AgentsMycobacterium avium ComplexMycobacterium avium-intracellulare InfectionDiarylquinolinesDrug Therapy, CombinationEthambutolHumansMacrolidesMicrobial Sensitivity TestsRifabutinRifampinRifamycinsSputumAnti-Bacterial AgentsAntitubercular AgentsbedaquilineDiarylquinolinesEthambutolMacrolidesRifabutinRifampinRifamycins

Identifiers

PMID41761389
PMCPMC13616200

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.